Entrepreneurial Lead of the NuclearMediX team and Postdoctoral Researcher at Imperial College London. Dr. Fu has extensive experience in drug development, from lead selection to pre-clinical stages. He specializes in developing and managing novel radioconjugates of small molecules, peptides, and antibodies.

Principal Scientific Advisor of NuclearMediX and inventor of the Fluoroethyl-triazole Octreotate ([18F]FET-βAG-TOCA, FETO) SSTR-PET tracer. Prof. Aboagye is a Fellow of the Academy of Medical Sciences (FMedSci) and Professor of Cancer Pharmacology & Molecular Imaging at Imperial College London. With over 15 years of pioneering research, he has 16 patents and 378 published articles, successfully translating multiple radiopharmaceutical drugs into clinical trials.

Dr. Spruce holds a PhD in Molecular Biology and Oncology and has over 10 years of experience as an academic. With formal training and experience in technology transfer, she supports the Faculty of Medicine in assessing research discoveries for commercial potential and advancing these technologies to market adoption. Her role focuses on accessing translational funds, industry collaboration, intellectual property protection, marketing, licensing, and spin-outs.